Literature DB >> 11106355

Epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome.

J R Engel1, A Smallwood, A Harper, M J Higgins, M Oshimura, W Reik, P N Schofield, E R Maher.   

Abstract

Beckwith-Wiedemann syndrome (BWS) is a model imprinting disorder resulting from mutations or epigenetic events involving imprinted genes at chromosome 11p15.5. Thus, germline mutations in CDKN1C, uniparental disomy (UPD), and loss of imprinting of IGF2 and other imprinted genes have been implicated. Many familial BWS cases have germline CDKN1C mutations. However, most BWS cases are sporadic and UPD or putative imprinting errors predominate in this group. We have identified previously a subgroup of sporadic cases with loss of imprinting (LOI) of IGF2 and epigenetic silencing of H19 proposed to be caused by a defect in a distal 11p15.5 imprinting control element (designated BWSIC1). However, many sporadic BWS patients show biallelic IGF2 expression in the presence of normal H19 methylation and expression patterns. This and other evidence suggested the existence of a further imprinting control element (BWSIC2) at 11p15. 5. Recently, we showed that a subgroup of BWS patients have loss of methylation (LOM) at a differentially methylated region (KvDMR1) within the KCNQ1 gene centromeric to the IGF2 and H19 genes. We have now analysed a large series of sporadic cases to define the frequency and phenotypic correlates of epigenetic abnormalities in BWS. LOM at KvDMR1 was detected by Southern analysis or a novel PCR based method in 35 of 69 (51%) sporadic BWS without UPD. LOM at KvDMR1 was often, but not invariably associated with LOI of IGF2. KvDMR1 LOM was not detected in BWS patients with putative BWSIC1 defects and cases with KvDMR1 LOM (that is, putative BWSIC2 defects) invariably had a normal H19 methylation pattern. The incidence of exomphalos in putative BWSIC2 defect patients was not significantly different from that in patients with germline CDKN1C mutations (20/29 and 13/15 respectively), but was significantly greater than that in patients with putative BWSIC1 defects (0/5, p=0.007) and UPD (0/22, p<0.0001). These findings are consistent with the hypothesis that LOM of KvDMR1 (BWSIC2 defect) results in epigenetic silencing of CDKN1C and variable LOI of IGF2. BWS patients with embryonal tumours have UPD or a BWSIC1 defect but not LOM of KvDMR1. This study has further shown how (1) variations in phenotypic expression of BWS may be linked to specific molecular subgroups and (2) molecular analysis of BWS can provide insights into mechanisms of imprinting regulation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106355      PMCID: PMC1734494          DOI: 10.1136/jmg.37.12.921

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  36 in total

1.  Imprinting mutation in the Beckwith-Wiedemann syndrome leads to biallelic IGF2 expression through an H19-independent pathway.

Authors:  K W Brown; A J Villar; W Bickmore; J Clayton-Smith; D Catchpoole; E R Maher; W Reik
Journal:  Hum Mol Genet       Date:  1996-12       Impact factor: 6.150

2.  Uniparental paternal disomy in a genetic cancer-predisposing syndrome.

Authors:  I Henry; C Bonaiti-Pellié; V Chehensse; C Beldjord; C Schwartz; G Utermann; C Junien
Journal:  Nature       Date:  1991-06-20       Impact factor: 49.962

3.  Epigenetic lesions at the H19 locus in Wilms' tumour patients.

Authors:  T Moulton; T Crenshaw; Y Hao; J Moosikasuwan; N Lin; F Dembitzer; T Hensle; L Weiss; L McMorrow; T Loew; W Kraus; W Gerald; B Tycko
Journal:  Nat Genet       Date:  1994-07       Impact factor: 38.330

Review 4.  Beckwith-Wiedemann syndrome.

Authors:  M Elliott; E R Maher
Journal:  J Med Genet       Date:  1994-07       Impact factor: 6.318

5.  Imprint switching on human chromosome 15 may involve alternative transcripts of the SNRPN gene.

Authors:  B Dittrich; K Buiting; B Korn; S Rickard; J Buxton; S Saitoh; R D Nicholls; A Poustka; A Winterpacht; B Zabel; B Horsthemke
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

6.  An imprinted gene p57KIP2 is mutated in Beckwith-Wiedemann syndrome.

Authors:  I Hatada; H Ohashi; Y Fukushima; Y Kaneko; M Inoue; Y Komoto; A Okada; S Ohishi; A Nabetani; H Morisaki; M Nakayama; N Niikawa; T Mukai
Journal:  Nat Genet       Date:  1996-10       Impact factor: 38.330

7.  Disruption of insulin-like growth factor 2 imprinting in Beckwith-Wiedemann syndrome.

Authors:  R Weksberg; D R Shen; Y L Fei; Q L Song; J Squire
Journal:  Nat Genet       Date:  1993-10       Impact factor: 38.330

8.  Mosaic uniparental disomy in Beckwith-Wiedemann syndrome.

Authors:  R E Slatter; M Elliott; K Welham; M Carrera; P N Schofield; D E Barton; E R Maher
Journal:  J Med Genet       Date:  1994-10       Impact factor: 6.318

9.  Imprinting mutations in the Beckwith-Wiedemann syndrome suggested by altered imprinting pattern in the IGF2-H19 domain.

Authors:  W Reik; K W Brown; H Schneid; Y Le Bouc; W Bickmore; E R Maher
Journal:  Hum Mol Genet       Date:  1995-12       Impact factor: 6.150

10.  Somatic overgrowth associated with overexpression of insulin-like growth factor II.

Authors:  I M Morison; D M Becroft; T Taniguchi; C G Woods; A E Reeve
Journal:  Nat Med       Date:  1996-03       Impact factor: 53.440

View more
  42 in total

1.  In vitro fertilization may increase the risk of Beckwith-Wiedemann syndrome related to the abnormal imprinting of the KCN1OT gene.

Authors:  Christine Gicquel; Véronique Gaston; Jacqueline Mandelbaum; Jean-Pierre Siffroi; Antoine Flahault; Yves Le Bouc
Journal:  Am J Hum Genet       Date:  2003-05       Impact factor: 11.025

Review 2.  Constitutional epimutation as a mechanism for cancer causality and heritability?

Authors:  Megan P Hitchins
Journal:  Nat Rev Cancer       Date:  2015-09-18       Impact factor: 60.716

Review 3.  Child health, developmental plasticity, and epigenetic programming.

Authors:  Z Hochberg; R Feil; M Constancia; M Fraga; C Junien; J-C Carel; P Boileau; Y Le Bouc; C L Deal; K Lillycrop; R Scharfmann; A Sheppard; M Skinner; M Szyf; R A Waterland; D J Waxman; E Whitelaw; K Ong; K Albertsson-Wikland
Journal:  Endocr Rev       Date:  2010-10-22       Impact factor: 19.871

4.  Chromosome 11 segmental paternal isodisomy in amniocytes from two fetuses with omphalocoele: new highlights on phenotype-genotype correlations in Beckwith-Wiedemann syndrome.

Authors:  F R Grati; L Turolla; P D'Ajello; A Ruggeri; M Miozzo; G Bracalente; D Baldo; L Laurino; R Boldorini; E Frate; N Surico; L Larizza; F Maggi; G Simoni
Journal:  J Med Genet       Date:  2007-01-26       Impact factor: 6.318

Review 5.  The placental imprintome and imprinted gene function in the trophoblast glycogen cell lineage.

Authors:  Louis Lefebvre
Journal:  Reprod Biomed Online       Date:  2012-04-04       Impact factor: 3.828

6.  Epigenetic alterations of H19 and LIT1 distinguish patients with Beckwith-Wiedemann syndrome with cancer and birth defects.

Authors:  Michael R DeBaun; Emily L Niemitz; D Elizabeth McNeil; Sheri A Brandenburg; Maxwell P Lee; Andrew P Feinberg
Journal:  Am J Hum Genet       Date:  2002-01-28       Impact factor: 11.025

7.  Alternative mechanisms associated with silencing of CDKN1C in Beckwith-Wiedemann syndrome.

Authors:  N Diaz-Meyer; Y Yang; S N Sait; E R Maher; M J Higgins
Journal:  J Med Genet       Date:  2005-08       Impact factor: 6.318

Review 8.  Investigating parent of origin effects in studies of type 2 diabetes and obesity.

Authors:  Evadnie Rampersaud; Braxton D Mitchell; Adam C Naj; Toni I Pollin
Journal:  Curr Diabetes Rev       Date:  2008-11

Review 9.  The importance of imprinting in the human placenta.

Authors:  Jennifer M Frost; Gudrun E Moore
Journal:  PLoS Genet       Date:  2010-07-01       Impact factor: 5.917

10.  Epigenotype-phenotype correlations in Silver-Russell syndrome.

Authors:  E L Wakeling; S Abu Amero; M Alders; J Bliek; E Forsythe; S Kumar; D H Lim; F MacDonald; D J Mackay; E R Maher; G E Moore; R L Poole; S M Price; T Tangeraas; C L S Turner; M M Van Haelst; C Willoughby; I K Temple; J M Cobben
Journal:  J Med Genet       Date:  2010-08-03       Impact factor: 6.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.